Alpha Teknova, Inc. (TKNO): Total Liabilities
$34.81M
As of 2025-12-31
$33.28M
As of 2026-06-30
-12.7%
3-year compound annual growth
+27.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $34.81M | -4.3% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $36.38M | -5.6% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $38.55M | -26.4% | 2025-03-07, Balance as of period end |
| 2022-12-31 | $52.38M | +124.7% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $23.31M | +121.9% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $10.51M | n/a | 2022-03-18, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $34.81M | -4.3% |
| Immucell Corp (ICCC) | 2025-12-31 | $15.48M | -12.0% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $170.73M | -46.5% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $12.39M | +53.8% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $87.8K | -94.9% |
| Biomerica Inc (BMRA) | 2026-05-31 | $4.13M | +124.4% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $57.22M | +20.8% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $338.60M | +3.7% |
| Neogen Corp (NEOG) | 2026-05-31 | $1.25B | -8.7% |
Compare TKNO, ICCC, NTLA, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗